Free Trial

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Barclays PLC

Medpace logo with Medical background

Barclays PLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 71.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,781 shares of the company's stock after acquiring an additional 8,275 shares during the quarter. Barclays PLC owned 0.06% of Medpace worth $6,603,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Signaturefd LLC boosted its holdings in Medpace by 4.9% in the second quarter. Signaturefd LLC now owns 559 shares of the company's stock valued at $230,000 after purchasing an additional 26 shares during the last quarter. Wealth Alliance boosted its stake in shares of Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company's stock valued at $399,000 after buying an additional 27 shares during the last quarter. Centaurus Financial Inc. grew its position in shares of Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after buying an additional 29 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company's stock worth $1,787,000 after buying an additional 32 shares during the last quarter. Finally, Lindenwold Advisors INC raised its holdings in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock valued at $676,000 after acquiring an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the subject of several research analyst reports. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and dropped their target price for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They issued a "buy" rating and a $404.00 price objective for the company. William Blair reaffirmed an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Finally, UBS Group cut Medpace from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of "Hold" and an average price target of $380.56.

Get Our Latest Stock Report on Medpace

Medpace Trading Up 0.6 %

MEDP traded up $2.13 during trading on Friday, reaching $337.28. 683,001 shares of the company were exchanged, compared to its average volume of 284,230. Medpace Holdings, Inc. has a 52 week low of $277.72 and a 52 week high of $459.77. The firm has a 50 day moving average of $339.14 and a 200 day moving average of $366.30. The stock has a market cap of $10.48 billion, a P/E ratio of 29.53, a PEG ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the previous year, the company posted $2.22 earnings per share. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Featured Stories

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Should you invest $1,000 in Medpace right now?

Before you consider Medpace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.

While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines